Somatostatin analogue scintigraphy in Merkel cell tumours

Durani, Benjamin; Klein, Arnold William; Henze, Marcus; Haberkorn, Uwe; Hartschuh, Wolfgang

doi:10.1046/j.1365-2133.2003.05338.x

Cited by 40 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The potential use of SRI in MCC staging remains controversial. Most studies involving 111 indium-octreotide scintigraphy [17,19,20,21] found this technique to be less sensitive than current imaging by CT scan or 18 F-fluorodeoxyglucose PET. In the largest series evaluating 20 patients with MCC, 111 indium-octreotide scintigraphy demonstrated a sensitivity of 78 and a specificity of 95%.…”

Section: Discussionmentioning

confidence: 99%

“…Papotti et al [29] reported SSTR2A transcripts in 9 out of 10 MCCs using RT-PCR, including 5 cases (50%) with high levels of SSTR2A transcripts, which is consistent with the expression of SSTR2A protein in 59.2% of tumours in our study. Durani et al [19] reported SSTR2A expression in all 5 MCC cases investigated using immunohistochemistry; however, the characteristics and validity of their antibody were unclear, and no controls were described. …”

Section: Discussionmentioning

confidence: 99%

“…This is supported by the ability of SRI to detect MCCs and their metastases [17,18,19,20,21,22] as well as some cases of tumoural response to somatostatin analogues [23,24,25,26,27,28]. However, the efficacy of SSTR-targeted imaging and therapy in MCC patients is not uniform, suggesting that the in situ expression of SSTRs in MCCs may be heterogeneous.…”

Section: Introductionmentioning

confidence: 95%

“…However, the efficacy of SSTR-targeted imaging and therapy in MCC patients is not uniform, suggesting that the in situ expression of SSTRs in MCCs may be heterogeneous. Though the presence of SSTR2A in MCC tumours has been suggested in 2 small studies [19,29], expression of SSTR2A and SSTR5 have not been investigated by immunohistochemistry with monoclonal antibodies in large series of MCC patients to date.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity

Gardair¹,

Samimi

Touzé

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Background/Aims: Merkel cell carcinoma (MCC) is a rare high-grade neuroendocrine tumour of the skin. It has been speculated that MCCs express somatostatin receptors (SSTRs), but this has never been assessed in a large series of MCCs. The main aim of this study was to assess the expression of SSTR2A and SSTR5 in MCC tumours. The secondary aims were to assess whether expression of SSTR was associated with the Ki67 proliferative index, Merkel cell polyomavirus (MCPyV) status, clinical characteristics and outcome. Methods: Clinical data and tumours were collected from an ongoing cohort of French patients with MCC. Immunohistochemistry was performed with anti-SSTR2A and anti-SSTR5 monoclonal antibodies, and tumours were classified into 3 groups: ‘no expression', ‘low expression' and ‘moderate expression' using an SSTR staining score. Results: SSTR expression was assessed for 105 MCC tissue samples from 98 patients, and clinical characteristics were available for 87 of them. SSTR expression was consistent between the primary skin tumour and the corresponding metastases for SSTR2A and SSTR5 in 3/7 and 6/7 cases, respectively. SSTR2A and SSTR5 were expressed in 58 cases (59.2%) and in 44 cases (44.9%), respectively. Overall, at least one SSTR was expressed in 75 tumours (76.5%). SSTR expression was not associated with clinical characteristics, Ki67 proliferative index, recurrence-free survival or MCC-specific survival. Expression of SSTR2A was associated with MCPyV status in MCC tumours but not SSTR5. Conclusion: SSTRs were expressed in a high proportion of MCCs, although expression was heterogeneous between tumours and was not associated with disease severity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity

Gardair¹,

Samimi

Touzé

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

show abstract

“…IMP3 is normally expressed in early embryonic tissues, and may also be expressed in a proportion of nonsmall cell lung carcinomas and pancreatic adenocarcinomas. Further, K homology domain-containing proteins may be overexpressed in high-grade neuroendocrine lung carcinomas and extrapulmonary small cell carcinomas [62][63].…”

Section: Discussionmentioning

confidence: 99%

Merkel cell carcinoma versus metastatic small cell primary bronchogenic carcinoma

Velez¹,

Jackson²,

Lisette³

et al. 2013

Our Dermatol Online

View full text Add to dashboard Cite

Introduction: Merkel cell carcinoma (MCC) of the skin is a rare, aggressive, malignant neuroendocrine neoplasm. The tumor classically demonstrates positive immunohistochemistry (IHC) staining for chromogranin A(ChrA), cytokeratin 20 (CK20), neuron specific enolase (NSE) and/or achaete-acute complex-like 1 (MASH1). The newly identified Merkel cell polyomavirus (MCPyV) has been found to be associated with most MCC cases. The primary histologic differential diagnoses of cutaneous MCC is small cell primary bronchogenic carcinoma (SCLC); moreover, both are of neuroendocrine origin. SCLC accounts for approximately 10-15% of all primary lung cancer cases; this histologic subtype is a distinct entity with biological and oncological features distinct from non-small cell lung cancer (NSCLC). In contradistinction to MCC, SCLC is classically IHC positive for cytokeratin 7 (CK7) and transcription factor (TTF-1). Similar to SCLC, MCC cell lines may be classified into two different biochemical subgroups designated as Classic and Variant. In our review and case report, we aim to emphasize the importance of a multidisciplinary approach to the approach to this difficult differential diagnosis. We also aim to comment about features of the cells of origin of MCC and SCLC; to summarize the microscopic features of both tumors; and to review their respective epidemiologic, clinical, prognostic and treatment features. We want to emphasize the initial workup study of the differential diagnosis patient, including evaluating clinical lymph nodes, a clinical history of any respiratory abnormality, and chest radiogram. If a diagnosis of primary cutaneous MCC is confirmed, classic treatment includes excision of the primary tumor with wide margins, excision of a sentinel lymph node, and computed tomography, positron emission tomography and/or Fluorine-18-fluorodeoxyglucose positron emission tomography scan studies.Key words: Merkel cell carcinoma; thyroid transcription factor; somatostatin; IMP3; small cell lung carcinoma (SCLC) Abbreviations and acronyms: Merkel cell carcinoma (MCC), thyroid transcription factor 1 (TTF-1), immunohistochemistry (IHC), neuron specific enolase (NSE), small cell lung carcinoma (SCLC), chromogranin A(CgA), insulin-like growth factor II mRNA binding protein 3 (IMP3), neurofilament protein (NF), cytokeratin 7 (CK7), cytokeratin 20 (CK20), surveillance, epidemiology, and end results (SEER), non-small cell lung cancer (NSCLC), computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), Merkel cell polyoma virus (MCPyV). MERKEL CELL CARCINOMA VERSUS METASTATIC SMALL CELL PRIMARY BRONCHOGENIC CARCINOMA IntroductionMerkel cell carcinoma (MCC) of the skin is an aggressive but rare malignant neuroendocrine tumor. This tumor has a high rate of recurrence and metastasis the main histopathological differential diagnosis is cell lung carcinoma (SCLC). Most MCC are usually positive to cytokeratin 20 (CK20) stain as well as may show some neuroendocrine differentiation, expressing eit...

show abstract

Somatostatin Receptor Scintigraphy in Other Tumors Imaging

Trofimiuk–Müldner

Hubalewska‐Dydejczyk

2015

Somatostatin Analogues

View full text Add to dashboard Cite

Somatostatin analogue scintigraphy in Merkel cell tumours

Abstract: These data confirm that scintigraphy with the radiolabelled somatostatin analogue octreotide is not clinically helpful in detecting metastases from Merkel cell carcinoma. In this relatively small sample the method generated false-positive or false-negative results in five of 11 cases.

Cited by 40 publications

References 20 publications

Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity

Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity

Merkel cell carcinoma versus metastatic small cell primary bronchogenic carcinoma

Somatostatin Receptor Scintigraphy in Other Tumors Imaging

Contact Info

Product

Resources

About